Literature DB >> 8250008

Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency.

K Okajima1, I Kohno, G Soe, H Okabe, K Takatsuki, B R Binder.   

Abstract

To examine whether or not acquired alpha 2-plasmin inhibitor deficiency is associated with systemic fibrinogenolysis, we analyzed the fibrin and fibrinogen degradation products in eight patients with this condition in various disease states. The underlying disease was gastric cancer in three patients, metastatic prostatic cancer in two, acute promyelocytic leukemia in two, and abdominal aortic aneurysm in one patient. In all eight patients, the alpha 2-plasmin inhibitor level was reduced to less than 50% of normal, and plasmin-alpha 2-plasmin inhibitor complex levels were increased. Immunoblotting of serum using an antifibrinogen antibody detected a 250 kDa protein (corresponding to fragments X or DY) in all eight patients. Fragment Y and D monomer were detected in seven of the eight patients, indicating the occurrence of systemic fibrinogenolysis. However, they were not detected in one patient with metastatic prostatic cancer. To determine whether or not fibrinogen degradation was also occurring in the patient without fragment Y, we characterized the 250 kDa protein in all eight patients. The protein was found to be fragment X in the metastatic prostatic cancer patient without fragment Y, while it was fragment DY in the other seven patients. Thus, systemic fibrinogenolysis was present in all eight patients. In the two patients with metastatic prostatic cancer, the level of alpha 2-plasmin inhibitor gradually increased with the reduction of tumor size by treatment. Fragment X, fragment Y, and D monomer were not detected when the alpha 2-plasmin inhibitor level exceeded 60% of normal in both patients. In the other six patients fragment Y and D monomer also disappeared when the alpha 2-plasmin inhibitor level exceeded 60% of normal. These findings suggest that systemic fibrinogenolysis only occurs when the plasma levels of alpha 2-plasmin inhibitor falls below 60% of normal due to activation of the fibrinolytic system by various pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8250008     DOI: 10.1002/ajh.2830450104

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure.

Authors:  Shun-Ichi Kimura; Jun Odawara; Takatoshi Aoki; Masayuki Yamakura; Masami Takeuchi; Yoshihiko Watanabe; Kosei Matsue
Journal:  Int J Hematol       Date:  2009-04-21       Impact factor: 2.490

Review 2.  Tranexamic acid: a review of its use in surgery and other indications.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Dynamic functional clot formation in patients undergoing endoscopic mucosal resection.

Authors:  Bernd Froessler; Leonardo Zorron Cheng Tao Pu; Natalie Aboustate; Amanda Ovenden; Rajvinder Singh
Journal:  JGH Open       Date:  2020-02-06

4.  Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients.

Authors:  T Wassenaar; J Black; B Kahl; B Schwartz; W Longo; D Mosher; E Williams
Journal:  Hematol Oncol       Date:  2008-12       Impact factor: 5.271

5.  Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.

Authors:  Mihoko Koseki; Noboru Asada; Hidetaka Uryu; Masami Takeuchi; Hidesaku Asakura; Kosei Matsue
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

6.  Intramuscular Bleeding Triggered by Disseminated Intravascular Coagulation with Enhanced Fibrinolysis in a Patient with Prostate Cancer.

Authors:  Eri Takada; Seiji Adachi; Yohei Horibe; Masahito Shimizu
Journal:  Intern Med       Date:  2021-10-12       Impact factor: 1.282

7.  Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report.

Authors:  Yoshihiro Wada; Mitsuhiro Uchiba; Yoshiaki Kawano; Nobuyuki Kai; Wataru Takahashi; Jiro Honda; Ken-Ichiro Tanoue; Yoshihiro Maeda; Yoji Murakami; Masatoshi Eto; Takahisa Imamura
Journal:  J Med Case Rep       Date:  2012-11-06

8.  Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix.

Authors:  Shawn Y Ong; Josephine Taverna; Clint Jokerst; Thomas Enzler; Emad Hammode; Elisa Rogowitz; Myke R Green; Hani M Babiker
Journal:  Case Rep Oncol Med       Date:  2015-11-03

9.  Serum apolipoprotein A-II and alpha-2-antiplasmin levels in midtrimester can be used as predictors of preterm delivery.

Authors:  Jianxia Huang; Yuhong Yang; Pei He
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.